Drug metabolism and disposition: the biological fate of chemicals, 25(2), 270-273 (1997-02-01)
Rats were orally co-administered sorivudine (SRV: 1-beta-D-arabinofuranosyl-(E)-5-(2-bromovinyl)uracil), a new oral antiviral drug for herpes zoster, with the oral anticancer drug tegafur (FT: 1-(2-tetrahydrofuryl)-5-fluorouracil) as a prodrug of 5-flourouracil (5-FU) once daily to investigate a toxicokinetic mechanism of 15 Japanese patients'
Clinical pharmacology and therapeutics, 61(5), 563-573 (1997-05-01)
Bromovinyl-uracil (BVU) is the principal metabolite of sorivudine, a potent anti-zoster nucleoside. BVU binds to, and irreversibly inhibits, the enzyme dihydropyrimidine dehydrogenase (DPD). The objective of this study was to assess the time course of recovery of DPD activity after
Antimicrobial agents and chemotherapy, 36(1), 214-216 (1992-01-01)
1-beta-D-Arabinofuranosyl-E-5-(2-bromovinyl)uracil (BV-araU) and E-5-(2-bromovinyl)uracil, a metabolite of BV-araU, did not affect either the anti-human immunodeficiency virus activity or the cytotoxicity of azidothymidine in MT-4 and MOLT-4 cells. Similarly, the bromovinyl compounds did not affect the in vitro antitumor activities of
Differential activity of potential antiviral nucleoside analogs on herpes simplex virus-induced and human cellular thymidine kinases.
Cheng YC, et al.
Antimicrobial Agents and Chemotherapy, 20(3), 420-423 (1981)
Simultaneous high-performance liquid chromatographic assay for 5-(2-bromo-E-ethenyl)-2'-deoxyuridine and its metabolite, 5-(2-bromo-E-ethenyl)uracil, in plasma.
Y Robinson et al.
Journal of chromatography, 338(1), 219-224 (1985-02-27)
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.